+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Exocrine Pancreatic Insufficiency: Trends Analysis, Forecast, 2015-2021

  • ID: 3774378
  • Report
  • Region: Global
  • 85 pages
  • Infinium Global Research
1 of 4
Global Revenue of Exocrine Pancreatic Insufficiency Market, was Valued at More than USD 700 Million in 2015, and is Projected to Surpass USD 1.2 Billion by 2021


  • Abbie Inc.
  • Allergan plc
  • AzuRx Biopharma Inc. MSD
  • Cilian AG
  • Digestive Carew Inc.
  • MORE
Exocrine pancreatic insufficiency (EPI) is a serious digestive problem and caused by improper digestion, and exocrine pancreatic insufficiency. It is a kind of a chronic disease caused by deficiency in pancreatic enzyme.

Global revenue of exocrine pancreatic insufficiency market, was valued at more than USD 700 million in 2015, and is projected to surpass USD 1.2 Billion by 2021. Furthermore, the global exocrine pancreatic market is anticipated to grow at a CAGR between 8.0%-8.6%.

Increasing global incidences for exocrine pancreatic insufficiency is one of the prime reasons increasing demand of advanced therapeutics globally. Furthermore, presence of significant number of pipeline drugs and lipase treatment in diabetic patients, optimizes the chymotrypsin and trypsin level are expected to drive the global market for exocrine pancreatic insufficiency market over the forecast period.

The EPI market has been segmented by the mode of disease management, therapeutics drugs, diagnostic tests and geography. Mode of disease management contains nutrition management, PERT. Therapeutics drugs consist Creon, Zenpep, Pancreaze, Ultresa and Pertzye.

The report covers the analysis of exocrine pancreatic insufficiency market by therapeutics and diagnostic tests. Furthermore, the report covers the analysis of global as well as regional markets of exocrine pancreatic insufficiency. North America dominated the global market of exocrine pancreatic insufficiency by accounting for the largest market share. While the Asia Pacific region is expected to grow at a highest CAGR over the forecast period 2016 - 2021.

The report provides deep insights on demand forecasts, market trends and micro and macro indicators. In addition, this report also provides insights on the factors that are driving and restraining the demand globally as well as regionally. Moreover, the Growth Matrix analysis given in the report brings an insight on the investment areas that existing or new market players can consider.

The report provides insights into the market using analytical tools such as Porter’s five forces analysis exocrine pancreatic insufficiency market. Moreover, the study highlights current market trends and provides forecast from 2016 to 2021. We also have highlighted future trends in the exocrine pancreatic insufficiency market that will impact the demand during the forecast period.

The Growth Matrix analysis provided in this report highlights key investing markets in the world. The competitive analysis given in each regional market brings an insight on the market share of the leading players. Additionally, the analysis highlights rise and fall in the market shares of the key players in the market.

The report on EPI market covers the companies such as Abbie, Inc., Allergan plc, Digestive Carew, Inc., Cilian AG, Anthera Pharmaceuticals, Inc. and AzuRx Biopharma, Inc. MSD.
Note: Product cover images may vary from those shown
2 of 4


  • Abbie Inc.
  • Allergan plc
  • AzuRx Biopharma Inc. MSD
  • Cilian AG
  • Digestive Carew Inc.
  • MORE
1. Preface
1.1. Report description
1.2. Market overview
1.3. Market segmentations
1.4. Competition
1.5. conclusion

2. Executive summary

3. Exocrine pancreatic insufficiency industry analysis
3.1. Introduction
3.2. market dynamics
3.2.1. Drivers
3.2.2. Restrains
3.2.3. Opportunities
3.3. competitive analysis
3.4. Porter’s five forces model
3.5. IGR- Growth matrix analysis

4. Exocrine pancreatic insufficiency regulatory aspects
4.1. North America
4.2. Europe
4.3. Asia Pacific
4.4. Rest of the world

5. Exocrine Pancreatic Insufficiency Market by Disease Management
5.1. Nutritional management
5.2. Pancreatic enzyme replacement therapy (PERT)
5.3. Life style modifications approach

6. Exocrine Pancreatic Insufficiency Market By Therapeutics Drugs
6.1. Creon
6.2. Zenpep
6.3. Pancreaze
6.4. Ultresa
6.5. Viokace
6.6. Pertzye

7. Exocrine Pancreatic Insufficiency Market By Diagnosis
7.1. Magnetic resonance imaging (MRI)
7.2. CT scanning
7.3. Endoscopic ultra-sonography (EUS)
7.4. Blood tests
7.5. Other tests

8. Exocrine Pancreatic Insufficiency Market By Geography
8.1. North America
8.2. Asia Pacific
8.3. Europe
8.4. South America
8.5. Rest of the world.

9. Company profile
9.1. Abbvie Inc.
9.2. Allergan plc.
9.3. Nordmark Arzneimittel GmbH & Co. KG
9.4. Digestive Care, Inc.
9.5. Cilian AG
9.6. Anthera Pharmaceuticals Inc.
9.7. Janssen Pharmaceuticals Inc.
9.8. AzurRx BioPharma Inc.
Note: Product cover images may vary from those shown
3 of 4


4 of 4
- Abbie Inc.
- Allergan plc
- Anthera Pharmaceuticals Inc.
- AzuRx Biopharma Inc. MSD
- Cilian AG
- Digestive Carew Inc.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/3774378